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Abstract 
Polymorphisms in the region of the interleukin-28B (IL28B)
gene have recently been associated with spontaneous and treatment
induced clearance of hepatitis C virus infection. The specific
 mechanisms of how IL28B polymorphisms affect HCV suppression
remain unknown. It is a matter of ongoing debate how to incorpo-
rate the IL28B data into the current treatment algorithms with
pegylated interferon-alpha and ribavirin. The eventual role of the
IL28B genotype in new therapeutic regimes with direct antiviral
agents needs to be explored in the ongoing and future clinical
 studies with these agents. (Acta gastro enterol. belg., 2011, 74, 000-
000).
Introduction
Recent genome wide association studies identified
several single nucleotide polymorphisms in and near the
IL28B gene locus of chromosome 19 that are correlated
with spontaneous and treatment induced clearance of
hepatitis C infection. The aim of this review is to summa-
rize the available data of the initial and subsequent
reports on IL28B, published prior to 31 January 2011 and
to elaborate on the possible clinical consequences of
their findings for the daily management of hepatitis C
patients in near future.
IL28B and treatment induced hepatitis C clear-
ance
Four independent genome-wide association studies
(GWAS) revealed several single nucleotide polymor-
phism sites (SNP) strongly associated with the response
to pegylated interferon-alpha (PEG-IFN) plus ribavirin
(RBV) treatment in chronic hepatitis C patients (1-4).
Genome-wide association studies allow an unbiased
sampling of variations in genes across the entire genome
without a hypothesis. The most important findings were
recently reviewed (5,6). The SNP are located near the
IL28B gene of chromosome 19, implicating a role for its
gene product, interferon (IFN)-λ3, in the immune
response to hepatitis C virus (HCV). The first GWAS
study that linked IL28B and HCV clearance came from
large cohorts of patients with genotype 1 chronic HCV
infection who were treated with PEG-IFN-α-2b or -2a
and RBV in the IDEAL study. The GWAS was per-
formed using an Illumina Human610Quad BeadChip
(San Diego, CA). The study included only compliant
subjects who were treated with a minimum number of
total doses (1). The strongest predictor of sustained viro-
logic response (SVR) was the rs12979860 SNP located
on the long arm of chromosome 19, within the IFN-λ
gene cluster. IL28B is upstream and in the reverse orien-
tation of IL28A ; rs12979860 is upstream of both of these
genes, closer to IL28B. Patients with the CC genotype
have SVR rates more than 2-fold higher than those with
the minor T allele. The magnitude of this association was
similar in the different population groups (European
Americans, African Americans, Hispanics). The
favourable CC genotype was a stronger baseline predic-
tor for SVR than baseline viremia below or above
600,000 IU/mL in the reported subgroup. Remarkably,
the C allele, associated with better treatment response,
was associated with higher baseline viral load (CC 6.35,
TC 6.33, TT 6.16 log10 IU/ml p = 1.21 × 10-10 ). The next
SNP most strongly associated with SVR found in the
GWAS was rs8099917, a non-coding SNP found
˜
7.5 kilobases upstream of the IL28B start codon. Other
groups used similar approaches to study the genetic basis
for SVR. Suppiah et al. studied Australians of European
descent with HCV genotype 1 infections who received
PEG-IFN-α and RBV (2). Several SNPs were associated
with clearance, but the strongest was rs8099917.
Compared with the T allele, heterozygosity for the minor
G allele was associated with a 1.64-fold increase in risk
for not responding to therapy and homozygosity was
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Spontaneous clearance was also more common in
hepatitis C patients with the rs12979860 CC genotype in
the well documented German rhesus prophylaxis anti-D
cohort (9). Jaundice during acute infection was more
 common among patients with CC genotype than non-CC
patients (with CT or TT) (p = 0.032). In CC patients,
jaundice during acute infection was not associated with
increased spontaneous clearance compared with those
without jaundice. In contrast, in non-CC patients,
 jaundice was associated with a higher likelihood of
 spontaneous clearance (42.9%) compared with those
without jaundice (13.7%). Women with the CT or TT
genotype who did not develop jaundice had a lower
chance of spontaneous clearance of HCV infection (9).
Similar findings were observed in patients from the
Australian Trial in Acute Hepatitis C (10). rs8099917 TT
homozygosity (versus GT/GG) was the only factor inde-
pendently predicting time to spontaneous clearance.
Participants with seroconversion illness with jaundice
were more frequently rs8099917 TT homozygotes than
other (GG/GT) genotypes (32% versus 5%, P = 0.047).
These data favour early therapeutic intervention in
patients with acute hepatitis C who do not develop jaun-
dice and exhibit an unfavourable IL28B genotype.
IL28B and immune response
The available results indicate the involvement of the
same IL28B SNPs in both innate spontaneous and treat-
ment-induced control of HCV infection. Collectively, the
results show that there is a genomic region comprising
IL28B and its potential regulatory sequences that is
strongly associated with IFN response. The IL28B gene
product IFN-λ3 belongs to the IFN-λ family, along with
IFN-λ1 and IFN-λ2, which are encoded by IL29 and
IL28A respectively. IFN-λs are categorized as type 3
IFNs and are potent, endogenous antiviral cytokines.
Although they are structurally most homologous to
members of the IL-10 family, IFN-λs are more function-
ally similar to type 1 IFNs (11,12). Several in vitro stud-
ies support a direct role for IFN-λ in the control of HCV
replication through the innate immune pathway. Robek
et al. showed that subgenomic and full-length HCV
replicons were inhibited by recombinant IFN-λ1 and
IFN-λ2, which up-regulated a representative interferon-
stimulated gene (ISG) (13). Carriers of the rs12979860 C
allele associated with resolution of HCV infection exhib-
ited increased serum IFN- λ levels. Moreover, high IFN-
λ levels predisposed to spontaneous resolution of HCV
infection (14). IFN-λs signal through a heterodimer that
comprises the interleukin-28 receptor α chain (IL-28Rα)
and the interleukin-10 receptor β chain (IL-10Rβ).
IL-28Rα is found primarily on epithelial cells. It is not
known which cells produce IFN-λs in the liver, but
 candidates include Kupffer cells, dendritic cells, and
liver sinusoidal endothelial cells. Downstream signalling
after IFN-λ receptor ligation is similar to type 1 IFN sig-
nalling and occurs via the covalently bound tyrosine
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associated with a 2.39-fold increase in risk. Tanaka et al
performed a GWAS using an Affymetrix SNP Array
(Santa Clara, CA) of DNA from HCV genotype
1–infected Japanese patients who achieved an SVR to
therapy with PEG-IFN-α-2a or PEG-IFN-α-2b and RBV,
comparing data with that of nonresponders (3). The
SNPs rs8099917 and rs12980275 segregated with treat-
ment response. Rauch et al. performed a GWAS of the
Swiss Hepatitis C Cohort, a population of European
white subjects infected with HCV genotypes 1 (48%), 2
(10%), 3 (29%), and 4 (9%) who received PEG-IFN-α
and RBV. The SNP rs8099917, also reported by Suppiah
et al. and Tanaka et al., was most highly associated with
response to treatment. 73.9% of patients homozygous for
the T allele achieved an SVR, but patients with the minor
G allele were 5-fold less likely to respond to therapy
(P = 3.11 × 10−8) (4). Genotyping of additional SNP’s
within the IL28B gene was performed by these groups in
an attempt to find out which single SNP or multiple-
allele haplotype would have the greatest associations
with treatment response. These genetic mapping studies
identified the specific alleles associated with response to
anti-HCV therapy : rs 12979860, 8099917, 8103142.
Multiple-allele haplotype signatures did not have a
 significantly greater association with SVR than any of
the individual SNPs.
The rs12979860 SNP findings were confirmed in an
independent patient registry from the Duke Hepatology
Clinical Research Database and Repository, a registry of
patients with HCV infections who were followed up lon-
gitudinally (7). The subjects had HCV genotype 1
(80.5%) or genotype 2 or 3 (19.5%) infections and had
received complete courses of PEG-IFN-α and RBV ther-
apy. White subjects, who made up most of the study
group, with the CC genotype were > 5 times more likely
to achieve an SVR than subjects with the CT or TT
 genotypes (P = 9.0 × 10−6). Presence of a CC genotype
predicted a sustained response with 65% sensitivity and
78% specificity in patients infected with HCV genotype
1. 
Alleles associated with clearance are more frequent in
East Asian populations, followed by European, European
American and Hispanic populations who have intermedi-
ate frequencies, while Afro-Americans and sub-Saharan
Africans have the lowest frequencies, accounting in part
for the observed racial differences in SVR (8). 
IL28B genotype in acute hepatitis C and
 spontaneous clearance of HCV
The same IL28B haplotypes associated with treatment
response are also associated with spontaneous clearance
of HCV. The rs12979860 CC genotype was more fre-
quently present in individuals who spontaneously
cleared the virus (n = 388) than in those who developed
persistent infection (n = 620) in a large natural history
cohort among individuals of both European and African
ancestry (8). 
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kinases Tyk2 and Jak1. These binding partners phospho-
rylate each other and also phosphorylate STAT1 and
STAT2 proteins. A consequence of phosphorylation of
STAT1 and STAT2 is the formation of the IFN-stimulat-
ed gene factor 3 complex along with activated IFN-regu-
latory factor 9, which leads to the up-regulation of
canonical ISGs. ISG up-regulation causes many of the
innate cellular defences against viral infection. 
Sensitivity to exogenous IFN is inversely associated
with levels of ISGs. Honda and Urban independently
showed in a Japanese and North American population
respectively that the good response IL28B variant is
strongly associated with lower pretreatment hepatic
expression levels of ISGs (15,16). IL28B genotypes
hence affect expression levels of ISGs, accounting for
the association between IL28B genotype and response to
therapy. 
The recently shown correlation between LDL choles-
terol and treatment response is also associated with
IL28B genotype. Subjects with the rs12979860 CC
responder genotype who are more likely to respond to
therapy have a higher baseline LDL cholesterol (17).
LDL cholesterol levels in chronic hepatitis C patients
may thus be a marker of host endogenous IFN response
to hepatitis C. 
IL28B genotype in non-genotype 1 hepatitis C
and other viral diseases
Studies of IL28B in patients infected with HCV of
other genotypes included small numbers and have
 produced conflicting data (4,7,18-21). Patients with the
rs8099917 TT genotype, in comparison with patients
with GT/GG genotypes, seem to have a significantly
higher rate of achieving rapid virologic response (RVR)
but not a significantly higher rate of achieving SVR in
the largest of these studies in genotype 2 and 3 subjects
who received standard duration therapy or who achieved
a rapid virologic response and received shortened
 therapy (12 weeks). The association between IL28B and
treatment response was only present among subjects who
did not achieve a rapid virologic response and received
24 weeks therapy. The effect of the IL28B haplotype
 status on treatment response might therefore be
 attenuated for genotypes 2 and 3. 
Polymorphisms in IL28B are not associated with
clearance of other viral infections such as HBV or
HIV (22-24). The association between favourable IL28B
SNP’s and spontaneous or treatment induced HCV clear-
ance does hold however in HIV co-infected patients who
have impaired immunological responses (4,8,25).
IL28B testing in Belgium in 2011 
In Belgium, genotyping of the IL28B gene (for one or
more SNPs) is reimbursed (as others molecular genetic
tests) if performed in one of the Genetic Centres
 formally recognized and funded by the health authorities.
These tests are reimbursed according to the nomen -
clature code B8000 per tested sample, which for 2011
corresponds to 319,98 euros per sample, of which
8,68 euros are at the charge of the patient. However, as
this reimbursement seems excessive considering the lab
cost for genotyping only one or two SNPs, the criteria for
reimbursement of these tests are currently being
reviewed by INAMI/RIZIV in order to reduce the cost
for the health care system. The time frame for the
 completion of this test is two weeks.
IL28B data and ongoing controversies
The data that are summarized above demonstrated that
the reported groups of patients who had a favorable
IL28B genotype also had a higher likelihood of clearing
hepatitis C virus (HCV) either spontaneously or with
combination PEG-IFN and RBV treatment ; however, at
this time, it seems appropriate to focus on some aspects
of the presented data that were not completely elucidated.
All of the clinical data regarding IL28B and treatment
responses have come from patient cohorts that were
 categorized as “adherent patients” or “patients who
received a minimum number of total doses,” and hence,
these studies should be labeled as modified intention-to-
treat analyses or per-protocol analyses. This approach
would allow for the identification of baseline factors that
are correlated with a favorable response to a given treat-
ment because it removes from the analyses the confound-
ing data from patients with suboptimal treatment
responses that resulted from suboptimal compliance.
However, at the same time, this approach would negate
the data from patients who discontinued therapy or had
critical dose reductions because of interferon-induced
side effects. Because the current data suggest that the
IL28B genotype is a marker of interferon sensitivity, it
may be that a number of patients who have a favorable
CC genotype and who had critical dose reductions or dis-
continued therapy because of interferon-induced side
effects were not included in these analyses. The positive
predictive value would, therefore, be lower in the actual
intention-to-treat setting than the values suggested by
these studies. Indeed, a poster that was presented at the
2010 AASLD Liver Meeting confirmed the strong corre-
lation between the IL28B CC genotype and the treat-
ment-induced response in an adherent patient group.
However, the odds ratio in the CC genotype patients was
much higher for RVR than for SVR, probably due to the
occurrence of more dropouts in the CC genotype group,
as mentioned on the poster (full paper currently not pub-
lished) (26). Although the association between the favor-
able IL28B genotype and the treatment-induced response
was present across races, the association was less strong
in African-Americans. Thus, it is notable that only 53%
of black subjects with the rs12979860 CC genotype
achieved an SVR compared to 82% of white subjects.
Genetic factors other than IL28B genotype mediate
 spontaneous and treatment-associated clearance of
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The correlation of IL28B genotype with clearance is
stronger for RVR than for SVR. Whereas patients with a
favorable IL28B genotype are more likely to achieve
RVR, RVR by itself is the strongest predictor of SVR,
regardless of IL28B genotype (19,30,31). Further studies
should be performed on these patients to investigate
IL28B genetics, ISG expression levels, and other genetic
factors involved in the response to anti-HCV therapy.
When IL28B genotype is combined with pretreatment
measurement of serum interferon-γ–inducible protein-10
(IP-10), the predictive value for the discrimination
between SVR and nonresponse is significantly
improved, especially in non-CC genotypes (28).
At present, international experts advocate genotype
stratification (CC vs. non-CC) in early-phase clinical
programs for direct antiviral agent (DAA) combination
therapy with PEG-IFN and RBV to rule out inclusion
bias in trials that are of limited sample size. One study
has reported evidence that the IL28B genotype is associ-
ated with SVR in subjects with chronic HCV who were
treated with the macrocyclic protease inhibitor telaprevir
in addition to the standard therapy. The population of this
study consisted of a relatively small number of patients
who were Japanese, predominantly of genotype 1b, and
were chronic HCV-naïve, HCV relapsers or non-respon-
sive patients who had a high prevalence of the favorable
IL28B rs8099917 TT genotype (32). A late-breaking
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HCV ; however, within a given race, IL28B genotype
does predict treatment outcome (5).
Speculations on the nature of the functional mecha-
nism underlying the IL28B HCV clearance association
have given rise to paradoxical issues. The finding that the
good response variant was associated with a higher
(although marginally so) baseline HCV-RNA is counter-
intuitive to all of the preceding clinical data from the
intention to treat analyses of major clinical trials that
showed an inverse correlation between HCV RNA and
SVR. There is yet another paradox in the association
between the IL28B pathway and its ISG status ; whereas
the up-regulation of ISGs would be expected to lead to
better innate control and viral clearance, the favorable
response variants have been correlated with low ISG sta-
tus in the chronic setting. Whether there is differential
gene expression between the acute and chronic settings
or whether the common signaling pathway is exhausted
in the chronic setting in patients with the unfavorable
genotypes are issues that remain speculative.
The functional mechanism that determines how a
 certain IL28B genotype influences the interferon
response remains to be elucidated, as IL28B mRNA
 levels in liver cells and IL28B levels in blood are similar
in HCV-infected individuals regardless of IL28B
 genotype (15,16).
It remains unclear how IL28B genotype would be a
marker of interferon responsiveness in genotype 1
 hepatitis C, but it is even less clear in non-genotype 1
hepatitis C or hepatitis B.
A recent multivariate analysis suggested that ISG
expression per se is a better predictor of the response to
treatment with PEG-IFN and ribavirin than IL28B geno-
type. The most accurate prediction of response was
obtained by using a four-gene classifier comprised of
IFI27, ISG15, RSAD2, and HTATIP2 (27). 
Impact of IL28B data on the management of
chronic hepatitis C patients
The favorable IL28B genotype associated with viral
clearance is present in approximately 25 to 40% of
European-American and European genotype 1 chronic
hepatitis C patients (7-9,18,19,28,29). The penetrance in
Belgian patients has not yet been reported, but it will
likely be of comparable magnitude. The majority of
genotype 1 patients de facto have a genotype that is not
conducive to SVR when judged on IL28B genotype
alone. Despite the strong association of IL28B with
clearance, there are people who carry IL-28B alleles that
are not associated with clearance but who do clear the
virus with PEG-IFN and RBV treatment, and there are
patients who have alleles that are associated with clear-
ance whose infection persists despite good adherence to
the treatment plan. Treatment-induced control of HCV
infection is affected by various host and viral factors at
baseline and by dynamic treatment parameters, which
are summarized in table 1.
Table 1. — Viral and host factors associated with response
to antiviral treatment with peginterferon ribavirin
 combination therapy for chronic hepatitis C
Abbreviations : 
RVR : rapid virologic response defined as HCV-RNA < lower limit
of detection at week 4 eRVR : extended rapid virologic response
defined as HCV-RNA < lower limit of detection at week 4 and week 12.
ISG : interferon stimulated gene.
IP-10 : interferon-γ–inducible protein-10.
Pretreatment Parameter On-Treatment Parameter
Genotype RVR
HCV RNA eRVR
IL28B polymorphisms (1-4) Compliance
Cirrhosis
Race
IP 10 (28,35) 
ISG status (36)






Vitamin D levels (41)
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presentation at the 2010 AASLD meeting that reported
on the interim results of a large, ongoing, international
multicenter trial in treatment-naïve genotype 1 HCV
patients showed no association between the IL28B geno-
type and RVR in the genotype 1 chronic HCV patients
treated with the second generation linear HCV protease
inhibitor TMC435 in combination with PEG-IFN-α-2a
and RBV treatment for 4 weeks (33). There was also no
evidence for a potential IL28B genotype influence on
genetically controlled interferon susceptibility, as judged
by early antiviral measures of efficacy after 4 weeks of
treatment with the nucleotide analog PSI-7977 in combi-
nation with PEG-IFN and RBV treatment in different
dosing groups that were stratified according to IL28B
genotype (34). The IL28B data from the boceprevir stud-
ies have not yet been made public. Thus, analyses of
completed and ongoing trials with DAA-based therapy
are awaited for clarification of whether baseline IL28B
genotype is associated with the initial RVR, the develop-
ment of viral resistance and the clinical endpoint of SVR.
The results of these studies will determine if baseline
IL28B genotype will have a place in the upcoming DAA-
based treatment algorithms. It is important to remind
physicians caring for HCV patients that, at present, we
lack a baseline multi-item signature of viral and host
parameters, let alone a single baseline parameter, such as
IL28B genotype, that predicts with 100% accuracy
whether a patient will not respond to the prescribed
antiviral therapy. Based on the current data, the presence
of treatment-induced RVR might well remain the most
applicable predictor of SVR in the clinic, regardless of
HCV genotype, IL28B genotype, or treatment regimen.
Furthermore, algorithms for stopping treatment that are
based on viral kinetics with a 100% NPV will remain
important to avoid exposure to therapy side effects in
patients who have no chance of SVR with continued
therapy.
Conclusions
Associations made between IL28B variants and HCV
clearance in large-scale genetic studies provide an
 exciting mechanistic link between innate immunity and
viral clearance. The IL28B genotype can be considered,
along with other factors, in predicting genotype 1 patient
responses to therapy with PEG-IFN and RBV.
Unfortunately, IL28B genotype does not have a positive
predictive value of 100% for SVR and cannot be used as
the only predictor of response. PEG-IFN and RBV ther-
apy should not be withheld based solely on the presence
of a less favourable IL28B genotype. Further investiga-
tion of the precise molecular mechanism(s) by which
IL28B genetic variation influences HCV outcomes is
warranted. The role of the IL28B genotype in future
 possible treatment algorithms with direct antiviral agents
needs to be explored in the ongoing and future clinical
studies. 
References
1. GE D., FELLAY J., THOMPSON A.J. et al. Genetic variation in IL28B
 predicts hepatitis C treatment-induced viral clearance. Nature, 2009,
461 (7262) : 399-401.
2. SUPPIAH V., MOLDOVAN M., AHLENSTIEL G. et al. IL28B is associat-
ed with response to chronic hepatitis C interferon-alpha and ribavirin  thera-
py. Nat. Genet., 2009, 41 (10) : 1100-4.
3. TANAKA Y., NISHIDA N., SUGIYAMA M. et al. Genome-wide association
of IL28B with response to pegylated interferon-alpha and ribavirin therapy
for chronic hepatitis C. Nat. Genet., 2009, 41 (10) : 1105-9.
4. RAUCH A., KUTALIK Z., DESCOMBES P. et al. Genetic Variation in
IL28B Is Associated With Chronic Hepatitis C and Treatment Failure : A
Genome-Wide Association Study. Gastroenterology, 2010, 138 (4) : 1338-45.
5. BALAGOPAL A., THOMAS D.L., THIO C.L. IL28B and the control of
 hepatitis C virus infection. Gastroenterology, 2010, 139 (6) : 1865-76.
6. AFDHAL N.H., MCHUTCHISON J.G., ZEUZEM S. et al. Hepatitis C
 pharmacogenetics : State of the art in 2010. Hepatology, 2011, 53 (1) : 336-
45.
7. MC CARTHY J.J., LI J.H., THOMPSON A. et al. Replicated association
between an IL28B gene variant and a sustained response to pegylated inter-
feron and ribavirin. Gastroenterology, 2010, 138 (7) : 2307-14.
8. THOMAS D.L., THIO C.L., MARTIN M.P. et al. Genetic variation in IL28B
and spontaneous clearance of hepatitis C virus. Nature, 2009, 461 (7265) :
798-801.
9. TILLMANN H.L., THOMPSON A.J., PATEL K. et al.A polymorphism near
IL28B is associated with spontaneous clearance of acute hepatitis C virus and
jaundice. Gastroenterology, 2010, 139 (5) : 1586-92.
10. GREBELY J., PETOUMENOS K., HELLARD M. et al. Potential role for
interleukin-28B genotype in treatment decision-making in recent hepatitis C
virus infection. Hepatology, 2010, 52 (4) : 1216-24.
11. GAD H.H., DELLGREN C., HAMMING O.J., VENDS S., PALUDAN S.R.,
HARTMANN R. Interferon-lambda is functionally an interferon but
 structurally related to the interleukin-10 family. J. Biol. Chem., 2009,
284 (31) : 20869-75.
12. DELLGREN C., GAD H.H., HAMMING O.J., MELCHJORSEN J.,
 HARTMANN R. Human interferon-lambda3 is a potent member of the type
III interferon family. Genes. Immun., 2009, 10 (2) : 125-31.
13. ROBEK M.D., BOYD B.S., CHISARI F.V. Lambda interferon inhibits
 hepatitis B and C virus replication. J. Virol., 2005, 79 (6) : 3851-4.
14. LANGHANS B., KUPFER B., BRAUNSCHWEIGER I. et al. Interferon-
lambda serum levels in hepatitis C. J. Hepatol., 2010.
15. HONDA M., SAKAI A., YAMASHITA T. et al. Hepatic ISG expression is
associated with genetic variation in interleukin 28B and the outcome of IFN
therapy for chronic hepatitis C. Gastroenterology, 2010, 139 (2) : 499-
509.
16. URBAN T.J., THOMPSON A.J., BRADRICK S.S. et al. IL28B genotype is
associated with differential expression of intrahepatic interferon-stimulated
genes in patients with chronic hepatitis C. Hepatology, 2010, 52 (6) : 1888-
96.
17. LI J.H., LAO X.Q., TILLMANN H.L. et al. Interferon-lambda genotype and
low serum low-density lipoprotein cholesterol levels in patients with chronic
hepatitis C infection. Hepatology, 2010, 51 (6) : 1904-11.
18. SCHERZER T.M., HOFER H., STAETTERMAYER A.F. et al. Early viro-
logic response and IL28B polymorphisms in patients with chronic hepatitis C
genotype 3 treated with peginterferon alfa-2a and ribavirin. J. Hepatol., 2010.
19. MANGIA A., THOMPSON A.J., SANTORO R. et al. An IL28B polymor-
phism determines treatment response of hepatitis C virus genotype 2 or
3 patients who do not achieve a rapid virologic response. Gastroenterology,
2010, 139 (3) : 821-7.
20. MONTES-CANO M.A., GARCIA-LOZANO J.R., ABAD-MOLINA C. et
al. Interleukin-28B genetic variants and hepatitis virus infection by different
viral genotypes. Hepatology, 2010, 52 (1) : 33-7.
21. YU M.-L., HUANG C.-F., HUANG J.-F. et al. Role of interleukin-28B poly-
morphisms in the treatment of hepatitis C virus genotype 2 infection in Asian
patients. Hepatology, 2011, 53 (1) : 7-13.
22. MARTIN M.P., QI Y., GOEDERT J.J. et al. IL28B polymorphism does not
determine outcomes of hepatitis B virus or HIV infection. J. Infect. Dis.,
2010, 202 (11) : 1749-53.
23. RALLON N.I., RESTREPO C., NAGGIE S. et al. Interleukin-28B gene
polymorphisms do not influence the susceptibility to HIV-infection or CD4
cell decline. Aids, 2010, 25 (2) : 269-71.
24. SALGADO M., KIRK G.D., COX A. et al. Protective interleukin-28B
 genotype affects hepatitis C virus clearance, but does not contribute to HIV-
1 control in a cohort of African-American elite controllers/suppressors. Aids,
2011, 25 (3) : 385-7.
Acta Gastro-Enterologica Belgica, Vol. LXXIV, April-June 2011
6 H. Orlent et al.
type-1 HCV patients : 24-week interim results from the PILLAR study.
Hepatology, 2010, 52 (Sup) : LB-5.
34. MC HUTCHISON J., GOLDSTEIN D., SHIANNA K.V. et al. IL28B SNP
geographical distribution and antiviral responses in a 28-day phase 2a trial of
PSI-7977 daily dosing plus PEG-IFN/RBV. Hepatology, 2010, 52 (Sup) :
815A.
35. LAGGING M., ROMERO AI., WESTIN J. et al. IP-10 predicts viral
response and therapeutic outcome in difficult-to-treat patients with HCV
genotype 1 infection. Hepatology, 2006, 44 (6) : 1617-25.
36. DILL M.T., DUONG F.H., VOGT J.E. et al. Interferon-Induced Gene
Expression Is a Stronger Predictor of Treatment Response Than IL28B
Genotype in Patients With Hepatitis C. Gastroenterology, 2010.
37. AKUTA N., SUZUKI F., KAWAMURA Y. et al. Predictive factors of early
and sustained responses to peginterferon plus ribavirin combination therapy
in Japanese patients infected with hepatitis C virus genotype 1b : amino acid
substitutions in the core region and low-density lipoprotein cholesterol levels.
J. Hepatol., 2007, 46 (3) : 403-10.
38. FREEDMAN N.D., CURTO T.M., LINDSAY K., WRIGHT E.C.,
SINHA R., EVERHART J.E. Coffee is associated with virological response
in chronic hepatitis C (CHC) : findings from the hepatitis C long-term
 treatment against cirrhosis trial (HALT-C). Hepatology, 2010, 52 (Sup) :
224A.
39. HARRISON S.A., ROSSARO L., HU K.Q. et al. Serum cholesterol and
statin use predict virological response to peginterferon and ribavirin therapy.
Hepatology, 2010, 52 (3) : 864-74.
40. SULKOWSKI M., HARRISON S.A., ROSSARO L. et al. Impaired fasting
glucose is associated with lower rates of sustained virologic response (SVR)
in patients with genotype 1 chronic hepatitis C (CHC) : retrospective analy-
sis of the IDEAL study. Hepatology, 2010, 52 (Sup) : 816A.
41. MOUCH S.A., ASSY N. Vitamin D supplementation improves viral response
in chronic hepatitis C genotype 2/3 patients treated with peginterferon-alpha
and ribavirin. Hepatology, 2010, 52 (Sup) : 809A.
Acta Gastro-Enterologica Belgica, Vol. LXXIV, April-June 2011
25. RALLON N.I., NAGGIE S., BENITO J.M. et al. Association of a single
nucleotide polymorphism near the interleukin-28B gene with response to
hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Aids, 2010,
24 (8) : F23-9.
26. MANGIA A., THOMPSON A., SANTORO R. et al. Rapid virological
response vs IL28B CC genotype in HCV-1 infected patients treated with an
individualized course of peginterferon and weight based ribavirin.
Hepatology, 2010 (52) : (S)A897.
27. DILL M.T., DUONG F.H., VOGT J.E. et al. Interferon-Induced Gene
Expression Is a Stronger Predictor of Treatment Response Than IL28B
Genotype in Patients With Hepatitis C. Gastroenterology, 2010, 140 (3) :
1021-31.
28. DARLING J.M., AERSSENS J., FANNING G. et al. Quantitation of pre-
treatment serum interferon-γ–inducible protein-10 improves the predictive
value of an IL28B gene polymorphism for hepatitis C treatment response.
Hepatology, 2011, 53 (1) : 14-22.
29. MONTES-CANO M.A., GARCÍA-LOZANO J.R., ABAD-MOLINA C. et
al. Interleukin-28B genetic variants and hepatitis virus infection by different
viral genotypes. Hepatology, 2010, 52 (1) : 33-7.
30. THOMPSON A.J., MUIR A.J., SULKOWSKI M.S. et al. Interleukin-28B
Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment
Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus.
Gastroenterology, 2010, 139 (1) : 120-9.
31. STATTERMAYER A.F., STAUBER R., HOFER H. et al. Impact of IL28B
Genotype on the Early and Sustained Virologic Response in Treatment-naive
Patients With Chronic Hepatitis C. Clin. Gastroenterol. Hepatol., 2011 : in
press.
32. AKUTA N., SUZUKI F., HIRAKAWA M. et al. Amino acid substitution in
hepatitis C virus core region and genetic variation near the interleukin 28B
gene predict viral response to telaprevir with peginterferon and ribavirin.
Hepatology, 2010, 52 (2) : 421-9.
33. FRIED M.W., BUTI M., DORE G.J. et al. Efficacy and safety of TMC435 in
combination with peginterferon alfa-2a and ribavirin in treatment-naive geno-
